Relay Therapeutics is approaching a pivotal clinical catalyst with the zovegalisib Phase 1/2 data readout at ESMO TAT. Check ...

It’s one thing to create your own relay-based computer; that’s already impressive enough, but what really makes [DiPDoT]’s ...

Shares of Relay Therapeutics were trading at $9.18 as of February 24. Over the last 52-week period, shares are up 182.15%. Given that these returns are generally positive, long-term shareholders are ...

Relay Therapeutics has laid off about 70 employees, the biotech's third round of cuts in less than a year. The most recent workforce reduction, along with other restructuring efforts made over the ...

Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced in first half of 2026Breast cancer triplet data ...

We’ve seen our share of blinking light projects around here; most are fairly straightforward small projects, but this entry to the 2025 One Hertz Challenge is the polar opposite of that approach.

A year and a half after banking $400 million in its series C round, Relay Therapeutics is ready to go public. The company filed to raise up to $200 million in its Nasdaq IPO, which will move two ...

Relay Therapeutics develops precision medicines targeting oncology and genetic diseases, leveraging proprietary computational technology.